PCI Biotech to present Phase I fimaVacc results at ESMO Immuno-Oncology 2019

Ads

You May Also Like

Coherus BioSciences Management to Present at 36th NASDAQ OMX Investor Program 

REDWOOD CITY, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today ...

Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with CellBridge Incorporated

MINNEAPOLIS, March 21, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the ...

Fate Therapeutics Reports First Quarter 2016 Financial Results

Phase 1/2 Clinical Trial of ProTmune™ for Prevention of Acute GvHD and CMV Infection ...